SCHEDULE: Balyasny Asset Management Discloses 9.99% Lexeo Stake

Balyasny Asset Management and its affiliates have disclosed a 9.99% passive beneficial ownership stake in Lexeo Therapeutics, Inc., totaling 8,345,651 shares.

Summary

• Balyasny Asset Management L.P. and its affiliates (BAM GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC, and Dmitry Balyasny) have reported a beneficial ownership of 8,345,651 shares of Lexeo Therapeutics, Inc. common stock.
• This represents approximately 9.99% of Lexeo Therapeutics' outstanding common stock.
• The ownership includes 4,336,514 shares issuable upon the exercise of warrants.
• The calculation is based on 33,196,997 shares outstanding as of May 12, 2025, as reported in Lexeo's Form 10-Q filed on May 15, 2025.
• A 9.99% beneficial ownership blocker prevents the reporting persons from exercising warrants if it would result in ownership exceeding this threshold.
• The shares are held by Atlas Diversified Master Fund, Ltd. (ADMF), a Cayman Islands exempted company, for which BAM acts as the investment manager.

Sentiment

Score: 6

Explanation: The disclosure of a significant passive institutional stake by a reputable firm like Balyasny Asset Management is generally a positive signal, indicating investor confidence. However, it's a factual ownership report, not an operational update, so the sentiment is moderately positive rather than strongly positive.

Positives

• Significant institutional investment by Balyasny Asset Management, indicating confidence in Lexeo Therapeutics.
• The filing is a passive 13G, suggesting the investor is not seeking to influence control, which can be viewed positively by existing management.

Risks

• The reporting persons are subject to a 9.99% beneficial ownership blocker, which contractually limits their ability to exercise warrants and increase their stake beyond this threshold.

Future Outlook

No forward-looking statements or guidance regarding Lexeo Therapeutics' future performance or operations are provided in this beneficial ownership disclosure.

Industry Context

This filing indicates continued institutional interest in the biotechnology and pharmaceutical sectors. A large passive stake by a prominent hedge fund like Balyasny Asset Management can signal perceived value or strategic positioning within the industry, potentially attracting further investor attention to Lexeo Therapeutics.

Comparison to Industry Standards

• A 9.99% stake is a significant position for an institutional investor in a public company, often signaling a long-term or strategic interest, aligning with typical large institutional holdings in emerging biotech firms.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding a nearly 10% stake may increase confidence and potentially attract other investors, signaling a vote of confidence in Lexeo Therapeutics.
• Management: The passive nature of the filing (Rule 13d-1(b)) suggests Balyasny Asset Management is not seeking to influence control, which is generally favorable for current management.

Key Dates

Recommendation

This Schedule 13G filing indicates a significant passive stake by Balyasny Asset Management, which is generally a positive signal of institutional confidence in Lexeo Therapeutics. However, the filing itself does not provide new operational or financial performance data to warrant a 'buy' or 'sell' recommendation. It primarily confirms a substantial existing position. Investors should 'hold' and monitor future operational updates and financial results from Lexeo Therapeutics to make further investment decisions.

Keywords

Lexeo Therapeutics, Balyasny Asset Management, Schedule 13G, beneficial ownership, institutional investment, common stock, warrants, passive stake, biotechnology, pharmaceuticals